1.            Goldstein, R. et al. The Effect of Levetiracetam Compared with Enzyme-Inducing Antiseizure Medications on Apixaban and Rivaroxaban Peak Plasma Concentrations. CNS Drugs 38, 399–408 (2024).

2.            Erenburg, N. et al. Stereoselective Analysis of the Antiseizure Activity of Fenfluramine and Norfenfluramine in Mice: Is l-Norfenfluramine a Better Follow-Up Compound to Racemic-Fenfluramine? Int. J. Mol. Sci. 25, (2024).

3.            Erenburg, N. et al. Pharmacokinetics of d- and l-norfenfluramine following their administration as individual enantiomers in rats. Epilepsia 65, e14–e19 (2024).

4.            Bialer, M. et al. Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). II. Drugs in more advanced clinical development. Epilepsia (2024) doi:10.1111/epi.18075.

5.            Bialer, M. et al. Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). I. Drugs in preclinical and early clinical development. Epilepsia (2024) doi:10.1111/epi.18056.

6.            Perucca, E., White, H. S. & Bialer, M. New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: II. Treatments in Clinical Development. CNS Drugs 37, 781–795 (2023).

7.            Perucca, E., Bialer, M. & White, H. S. New GABA-Targeting Therapies for the Treatment of Seizures and Epilepsy: I. Role of GABA as a Modulator of Seizure Activity and Recently Approved Medications Acting on the GABA System. CNS Drugs 37, 755–779 (2023).

8.            Erenburg, N., Hamed, R., Shaul, C., Perucca, E. & Bialer, M. Comparative activity of the enantiomers of fenfluramine and norfenfluramine in rodent seizure models, and relationship with their concentrations in plasma and brain. Epilepsia 64, 1673–1683 (2023).

9.            Goldstein, R. et al. Interactions Between Direct Oral Anticoagulants (DOACs) and Antiseizure Medications: Potential Implications on DOAC Treatment. CNS Drugs (2023) doi:10.1007/s40263-023-00990-0.

10.          Bialer, M. et al. Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): I. Drugs in preclinical and early clinical development. Epilepsia 63, 2865–2882 (2022).

11.          Bialer, M. et al. Progress report on new antiepileptic drugs: A summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): II. Drugs in more advanced clinical development. Epilepsia 63, 2883–2910 (2022).

12.          Wanounou, M., Caraco, Y., Levy, R. H., Bialer, M. & Perucca, E. Clinically Relevant Interactions Between Ritonavir-Boosted Nirmatrelvir and Concomitant Antiseizure Medications: Implications for the Management of COVID-19 in Patients with Epilepsy. Clin. Pharmacokinet. 61, 1219–1236 (2022).

13.          Shaul, C. et al. Phenytoin Metabolic Ratio, a Marker of CYP2C9 Activity, is Superior to the CYP2C9 Genotype as a Predictor of (S)-Warfarin Clearance. Clin. Pharmacokinet. 61, 1187–1198 (2022).

14.          Bialer, M. & Perucca, E. Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine? CNS Drugs 36, 113–122 (2022).

15.          Odi, R., Invernizzi, R. W., Gallily, T., Bialer, M. & Perucca, E. Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know. Pharmacol. Ther. 226, (2021).

16.          Odi, R. et al. Synthesis and enantioselective pharmacokinetic/ pharmacodynamic analysis of new CNS-active sulfamoylphenyl carbamate derivatives. Int. J. Mol. Sci. 22, (2021).

17.          Franco, V., Bialer, M. & Perucca, E. Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research. Neuropharmacology 185, (2021).

18.          Odi, R., Franco, V., Perucca, E. & Bialer, M. Bioequivalence and switchability of generic antiseizure medications (ASMs): A re-appraisal based on analysis of generic ASM products approved in Europe. Epilepsia 62, 285–302 (2021).

19.          Franco, V., Gershkovich, P., Perucca, E. & Bialer, M. The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations. Clin. Pharmacokinet. 59, 1493–1500 (2020).

20.          Bialer, M. et al. Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). I. Drugs in preclinical and early clinical development. Epilepsia 61, 2340–2364 (2020).

21.          Bialer, M. et al. Progress report on new antiepileptic drugs: A summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). II. Drugs in more advanced clinical development. Epilepsia 61, 2365–2385 (2020).

22.          Bialer, M. & Perucca, E. Response: Cannabidiol antiseizure activity and its interactions with clobazam: “It’s déjà vu all over again” Yogi Berra. Epilepsia 61, 1793–1794 (2020).

23.          Odi, R., Bibi, D., Wager, T. & Bialer, M. A perspective on the physicochemical and biopharmaceutic properties of marketed antiseizure drugs—From phenobarbital to cenobamate and beyond. Epilepsia 61, 1543–1552 (2020).

24.          Perucca, E. & Bialer, M. Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications. CNS Drugs 34, 795–800 (2020).

25.          Bialer, M. & Perucca, E. Does cannabidiol have antiseizure activity independent of its interactions with clobazam? An appraisal of the evidence from randomized controlled trials. Epilepsia 61, 1082–1089 (2020).

26.          Bibi, D. & Bialer, M. Pharmacokinetic and pharmacodynamic analysis of (2S,3S)-sec-butylpropylacetamide (SPD) in rats and pigs—A CNS-active stereoisomer of SPD. Epilepsia 61, 149–156 (2020).

27.          Bialer, M. et al. Novel treatment approaches and pediatric research networks in status epilepticus. Epilepsy Behav. 101, (2019).

28.          Lin, Y. L., Bialer, M., Cabrera, R. M., Finnell, R. H. & Wlodarczyk, B. J. Teratogenicity of valproic acid and its constitutional isomer, amide derivative valnoctamide in mice. Birth Defects Res. 111, 1013–1023 (2019).

29.          Bialer, M. et al. A summary of data presented at the XIV conference on new antiepileptic drug and devices (EILAT XIV). Epilepsy Res. 153, 66–67 (2019).

30.          Haines, K. M. et al. Comparative efficacy of valnoctamide and sec-butylpropylacetamide (SPD) in terminating nerve agent–induced seizures in pediatric rats. Epilepsia 60, 315–321 (2019).

31.          Bibi, D., Shusterman, B., Nocentini, A., Supuran, C. T. & Bialer, M. Stereoselective pharmacokinetic and pharmacodynamic analysis of a CNS-active sulphamoylphenyl carbamate derivative. J. Enzyme Inhib. Med. Chem. 34, 1078–1082 (2019).

32.          Bialer, M. et al. Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). I. Drugs in preclinical and early clinical development. Epilepsia 59, 1811–1841 (2018).

33.          Bialer, M. et al. Progress report on new antiepileptic drugs: A summary of the Fourteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIV). II. Drugs in more advanced clinical development. Epilepsia 59, 1842–1866 (2018).

34.          Kudin, A. P. et al. Mitochondrial liver toxicity of valproic acid and its acid derivatives is related to inhibition of α-lipoamide dehydrogenase. Int. J. Mol. Sci. 18, (2017).

35.          Bibi, D. et al. Design and Comparative Evaluation of the Anticonvulsant Profile, Carbonic-Anhydrate Inhibition and Teratogenicity of Novel Carbamate Derivatives of Branched Aliphatic Carboxylic Acids with 4-Aminobenzensulfonamide. Neurochem. Res. 42, 1972–1982 (2017).

36.          Weiser, M. et al. A randomized, double-blind, placebo- and risperidone-controlled study on valnoctamide for acute mania. Bipolar Disord. 19, 285–294 (2017).

37.          Kaufmann, D. et al. sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain. Pharmacol. Res. 117, 129–139 (2017).

38.          Bialer, M. et al. Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII). Epilepsia 58, 181–221 (2017).

39.          Bialer, M. et al. Seizure detection and neuromodulation: A summary of data presented at the XIII conference on new antiepileptic drug and devices (EILAT XIII). Epilepsy Res. 130, 27–36 (2017).

40.          Shaul, C., Blotnick, S., Muszkat, M., Bialer, M. & Caraco, Y. Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects. Mol. Diagnosis Ther. 21, 75–83 (2017).

41.          Kaufmann, D. et al. Sec -Butylpropylacetamide (SPD) has antimigraine properties. Cephalalgia 36, 924–935 (2016).

42.          Mawasi, H. et al. Pharmacokinetic-pharmacodynamic correlation and brain penetration of sec-butylpropylacetamide, a new CNS drug possessing unique activity against status epilepticus. Mol. Pharm. 13, 2492–2496 (2016).

43.          Mawasi, H., Bibi, D. & Bialer, M. Design and comparative anticonvulsant activity assessment of CNS-active alkyl-carbamoyl imidazole derivatives. Bioorganic Med. Chem. 24, 4246–4253 (2016).

44.          Korczyn, A. D. et al. Third International Congress on Epilepsy, Brain and Mind: Part 1. Epilepsy Behav. 50, 116–137 (2015).

45.          Wlodarczyk, B. J., Ogle, K., Lin, L. Y., Bialer, M. & Finnell, R. H. Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice. Bipolar Disord. 17, 615–625 (2015).

46.          Shekh-Ahmad, T., Mawasi, H., McDonough, J. H., Yagen, B. & Bialer, M. The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus. Epilepsy Behav. 49, 298–302 (2015).

47.          Mawasi, H., Shekh-Ahmad, T., Finnell, R. H., Wlodarczyk, B. J. & Bialer, M. Pharmacodynamic and pharmacokinetic analysis of CNS-active constitutional isomers of valnoctamide and sec-butylpropylacetamide - Amide derivatives of valproic acid. Epilepsy Behav. 46, 72–78 (2015).

48.          Bialer, M. et al. Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Res. 111, 85–141 (2015).

49.          Shekh-Ahmad, T. et al. Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS-active carbamate derivatives of valproic acid. Epilepsia 55, 1944–1952 (2014).

50.          Bar-Klein, G. et al. Sec-Butyl-propylacetamide (SPD) and two of its stereoisomers rapidly terminate paraoxon-induced status epilepticus in rats. Epilepsia 55, 1953–1958 (2014).

51.          Shekh-Ahmad, T. et al. Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential. Epilepsia 55, 353–361 (2014).

52.          Karalis, V., MacHeras, P. & Bialer, M. Generic products of antiepileptic drugs: A perspective on bioequivalence, bioavailability, and formulation switches using monte carlo simulations. CNS Drugs 28, 69–77 (2014).

53.          Shekh-Ahmad, T., Hen, N., McDonough, J. H., Yagen, B. & Bialer, M. Valnoctamide and sec-butyl-propylacetamide (SPD) for acute seizures and status epilepticus. Epilepsia 54, 99–102 (2013).

54.          Neuman, M. G., Nanau, R. M., Shekh-Ahmad, T., Yagen, B. & Bialer, M. Valproic acid derivatives signal for apoptosis and repair in vitro. Clin. Biochem. 46, 1532–1537 (2013).

55.          Karalis, V., Bialer, M. & Macheras, P. Quantitative assessment of the switchability of generic products. Eur. J. Pharm. Sci. 50, 476–483 (2013).

56.          Mareš, P., Kubová, H., Hen, N., Yagen, B. & Bialer, M. Derivatives of valproic acid are active against pentetrazol-induced seizures in immature rats. Epilepsy Res. 106, 64–73 (2013).

57.          Hen, N. et al. Stereoselective pharmacodynamic and pharmacokinetic analysis of sec -butylpropylacetamide (SPD), a new CNS-Active derivative of valproic acid with unique activity against status epilepticus. J. Med. Chem. 56, 6467–6477 (2013).

58.          Onishi, Y. et al. Teratology study of amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide in NMRI mice. Birth Defects Res. Part B - Dev. Reprod. Toxicol. 98, 318–327 (2013).

59.          Elger, C. et al. Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. Epilepsia 54, 1453–1461 (2013).

60.          Bialer, M., Shekh-Ahmad, T., Braun, T. L. & Halvorsen, M. B. Comparative steady-state pharmacokinetic evaluation of immediate-release topiramate and USL255, a once-daily extended-release topiramate formulation. Epilepsia 54, 1444–1452 (2013).

61.          Modi, H. R. et al. Propylisopropylacetic acid (PIA), a constitutional isomer of valproic acid, uncompetitively inhibits arachidonic acid acylation by rat acyl-CoA synthetase 4: A potential drug for bipolar disorder. Biochim. Biophys. Acta - Mol. Cell Biol. Lipids 1831, 880–886 (2013).

62.          Pouliot, W. et al. A comparative electrographic analysis of the effect of sec-butyl-propylacetamide on pharmacoresistant status epilepticus. Neuroscience 231, 145–156 (2013).

63.          Bialer, M. et al. Progress report on new antiepileptic drugs: A summary of the Eleventh Eilat Conference (EILAT XI). Epilepsy Res. 103, 2–30 (2013).

64.          Smith, P. & Bialer, M. The borderland of epilepsy: Chairs’ Symposium, 10th European Congress on Epileptology, London--October 1, 2012. Introduction. Epilepsia 53 Suppl 7, 1–2 (2012).

65.          Bialer, M. Comments on the working group’s 2012 review of the Program. Epilepsia 53, 1844–1846 (2012).

66.          Bialer, M. Chemical properties of antiepileptic drugs (AEDs). Adv. Drug Deliv. Rev. 64, 887–895 (2012).

67.          Bialer, M. & Soares-Da-Silva, P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia 53, 935–946 (2012).

68.          Bejarano-Achache, I. et al. Effects of CYP4F2 Polymorphism on Response to Warfarin During Induction Phase: A Prospective, Open-Label, Observational Cohort Study. Clin. Ther. 34, 811–823 (2012).

69.          Hen, N., Bialer, M. & Yagen, B. Syntheses and evaluation of anticonvulsant activity of novel branched alkyl carbamates. J. Med. Chem. 55, 2835–2845 (2012).

70.          Shekh-Ahmad, T., Bialer, M. & Yavin, E. Synthesis and anticonvulsant evaluation of dimethylethanolamine analogues of valproic acid and its tetramethylcyclopropyl analogue. Epilepsy Res. 98, 238–246 (2012).

71.          Bialer, M. How did phenobarbital’s chemical structure affect the development of subsequent antiepileptic drugs (AEDs)? Epilepsia 53 Suppl 8, 3–11 (2012).

72.          Bialer, M. & Smith, P. E. Special issue: Phenobarbital: the Centenary - 10th European Congress on Epileptology, London - October 1, 2012. Introduction. Epilepsia 53 Suppl 8, 1–2 (2012).

73.          Bialer, M. Why are antiepileptic drugs used for nonepileptic conditions? Epilepsia 53 Suppl 7, 26–33 (2012).

74.          Chang, P. et al. The antiepileptic drug valproic acid and other medium-chain fatty acids acutely reduce phosphoinositide levels independently of inositol in Dictyostelium. DMM Dis. Model. Mech. 5, 115–124 (2012).

75.          White, H. S. et al. A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. Epilepsia 53, 134–146 (2012).

76.          Pessah, N. et al. Design and pharmacological activity of glycinamide and N-methoxy amide derivatives of analogs and constitutional isomers of valproic acid. Epilepsy Behav. 22, 461–468 (2011).

77.          Lambrecht, L. J., Shekh-Ahmad, T., Todd, W. M., Halvorsen, M. B. & Bialer, M. Comparative pharmacokinetic analysis of USL255, a new once-daily extended-release formulation of topiramate. Epilepsia 52, 1877–1883 (2011).

78.          Hen, N. et al. Anticonvulsant 4-aminobenzenesulfonamide derivatives with branched-alkylamide moieties: X-ray crystallography and inhibition studies of human carbonic anhydrase isoforms I, II, VII, and XIV. J. Med. Chem. 54, 3977–3981 (2011).

79.          Bialer, M. et al. Progress report on new antiepileptic drugs: A summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res. 92, 89–124 (2010).

80.          Pessah, N. et al. Comparative pharmacodynamic and pharmacokinetic analysis of two anticonvulsant halo derivatives of 2,2,3,3-tetramethylcyclopropanecarboxamide, an amide of a cyclic analog of valproic acid. Epilepsia 51, 1944–1953 (2010).

81.          Bialer, M. & Midha, K. K. Generic products of antiepileptic drugs: A perspective on bioequivalence and interchangeability. Epilepsia 51, 941–950 (2010).

82.          Kaufmann, D. et al. Evaluation of the antiallodynic, teratogenic and pharmacokinetic profile of stereoisomers of valnoctamide, an amide derivative of a chiral isomer of valproic acid. Neuropharmacology 58, 1228–1236 (2010).

83.          Hen, N., Bialer, M., Wlodarczyk, B., Finnell, R. H. & Yagen, B. Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide. J. Med. Chem. 53, 4177–4186 (2010).

84.          Shimshoni, J. A. et al. Evaluation of stereoselective anticonvulsant, teratogenic, and pharmacokinetic profile of valnoctylurea (capuride): A chiral stereoisomer of valproic acid urea derivative. Epilepsia 51, 323–332 (2010).

85.          Bialer, M. & White, H. S. Key factors in the discovery and development of new antiepileptic drugs. Nat. Rev. Drug Discov. 9, 68–82 (2010).

86.          Bialer, M. Pharmacodynamic and pharmacokinetic characteristics of intravenous drugs in status epilepticus. Epilepsia 50, 44–48 (2009).

87.          Kaufmann, D., Bialer, M., Shimshoni, J. A., Devor, M. & Yagen, B. Synthesis and evaluation of antiallodynic and anticonvulsant activity of novel amide and urea derivatives of valproic acid analogues. J. Med. Chem. 52, 7236–7248 (2009).

88.          Okada, A. et al. Anticonvulsant profile and teratogenic evaluation of potent new analogues of a valproic acid urea derivative in NMRI mice. Birth Defects Res. Part B - Dev. Reprod. Toxicol. 86, 394–401 (2009).

89.          Zannikos, P. et al. Pharmacokinetics of carisbamate (RWJ-333369) in healthy Japanese and Western subjects. Epilepsia 50, 1850–1859 (2009).

90.          Shimshoni, J. A., Bialer, M. & Yagen, B. Synthesis and anticonvulsant activity of aromatic tetramethylcyclopropanecarboxamide derivatives. Bioorganic Med. Chem. 16, 6297–6305 (2008).

91.          Almeida, L., Bialer, M. & Soares-da-Silva, P. Eslicarbazepine Acetate. in The Treatment of Epilepsy: Third Edition 485–498 (John Wiley and Sons, 2009). doi:10.1002/9781444316667.ch38.

92.          Pessah, N., Bialer, M., Wlodarczyk, B., Finnell, R. H. & Yagen, B. α-fluoro-2,2,3,3-tetramethylcyclopropanecarboxamide, a novel potent anticonvulsant derivative of a cyclic analogue of valproic acid. J. Med. Chem. 52, 2233–2242 (2009).

93.          Elger, C. & Bialer, M. Epilepsia: Foreword. Epilepsia 50, 1 (2009).

94.          Shimshoni, J. A. et al. Evaluation of the effects of propylisopropylacetic acid (PIA) on neuronal growth cone morphology. Neuropharmacology 56, 831–837 (2009).

95.          Bialer, M. et al. Progress report on new antiepileptic drugs: A summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 83, 1–43 (2009).

96.          Okada, A. et al. Tetramethylcyclopropyl analogue of the leading antiepileptic drug, valproic acid: Evaluation of the teratogenic effects of its amide derivatives in NMRI mice. Birth Defects Res. Part A - Clin. Mol. Teratol. 82, 610–621 (2008).

97.          Shimshoni, J. A. et al. Anticonvulsant profile and teratogenicity of 3,3-dimethylbutanoylurea: A potential for a second generation drug to valproic acid. Epilepsia 49, 1202–1212 (2008).

98.          Kaufmann, D. et al. Evaluation of the enantioselective antiallodynic and pharmacokinetic profile of propylisopropylacetamide, a chiral isomer of valproic acid amide. Neuropharmacology 54, 699–707 (2008).

99.          Shimshoni, J. A., Bialer, M., Wlodarczyk, B., Finnell, R. H. & Yagen, B. Potent anticonvulsant urea derivatives of constitutional isomers of valproic acid. J. Med. Chem. 50, 6419–6427 (2007).

100.        Bialer, M. Clinical pharmacology of parenteral use of antiepileptic drugs. Epilepsia 48, 46–48 (2007).

101.        Bialer, M. Generic products of antiepileptic drugs (AEDs): Is it an issue? Epilepsia 48, 1825–1832 (2007).

102.        Perucca, E., French, J. & Bialer, M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol. 6, 793–804 (2007).

103.        Bialer, M. Extended-release formulations for the treatment of epilepsy. CNS Drugs 21, 765–774 (2007).

104.        Chien, S. et al. An interaction study between the new antiepileptic and CNS drug carisbamate (RWJ-333369) and lamotrigine and valproic acid. Epilepsia 48, 1328–1338 (2007).

105.        Mannens, G. S. J. et al. The absorption, metabolism, and excretion of the novel neuromodulator RWJ-333369 (1,2-ethanediol, [1-2-chlorophenyl]-, 2-carbamate, [S]-) in humans. Drug Metab. Dispos. 35, 554–565 (2007).

106.        Elger, C. et al. Eslicarbazepine acetate: A double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures. Epilepsia 48, 497–504 (2007).

107.        Shimshoni, J. A. et al. The effects of central nervous system-active valproic acid constitutional isomers, cyclopropyl analogs, and amide derivatives on neuronal growth cone behavior. Mol. Pharmacol. 71, 884–892 (2007).

108.        Bialer, M. & Yagen, B. Valproic Acid: Second Generation. Neurotherapeutics 4, 130–137 (2007).

109.        Bialer, M. et al. Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII). Epilepsy Res. 73, 1–52 (2007).

110.        Sobol, E. et al. Anticonvulsant activity, neural tube defect induction, mutagenicity and pharmacokinetics of a new potent antiepileptic drug, N-methoxy-2,2,3,3-tetramethylcyclopropane carboxamide. Epilepsy Res. 73, 75–84 (2007).

111.        Chien, S. et al. Pharmacokinetic interaction study between the new antiepileptic and CNS drug RWJ-333369 and carbamazepine in healthy adults. Epilepsia 47, 1830–1840 (2006).

112.        Yao, C., Doose, D. R., Novak, G. & Bialer, M. Pharmacokinetics of the new antiepileptic and CNS drug RWJ-333369 following single and multiple dosing to humans. Epilepsia 47, 1822–1829 (2006).

113.        Eyal, S. et al. The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver. Br. J. Pharmacol. 149, 250–260 (2006).

114.        Sobol, E. et al. Preclinical evaluation of 2,2,3,3-tetramethylcyclopropanecarbonyl-urea, a novel, second generation to valproic acid, antiepileptic drug. Neuropharmacology 51, 933–946 (2006).

115.        Okada, A. et al. Teratology study of derivatives of tetramethylcyclopropyl amide analogues of valproic acid in mice. Birth Defects Res. Part B - Dev. Reprod. Toxicol. 77, 227–233 (2006).

116.        Bialer, M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin. Investig. Drugs 15, 637–647 (2006).

117.        Bialer, M. The pharmacokinetics and interactions of new antiepileptic drugs: An overview. Ther. Drug Monit. 27, 722–726 (2005).

118.        Winkler, I. et al. Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain. Br. J. Pharmacol. 146, 198–208 (2005).

119.        Winkler, I. et al. Efficacy of antiepileptic tetramethylcyclopropyl analogues of valproic acid amides in a rat model of neuropathic pain. Neuropharmacology 49, 1110–1120 (2005).

120.        Sobol, E. et al. Pharmacokinetics and metabolism of a new potent antiepileptic drug, 2,2,3,3-tetramethycyclopropanecarbonylurea, in rats. Drug Metab. Dispos. 33, 1538–1546 (2005).

121.        Mimrod, D. et al. A comparative study of the effect of carbamazepine and valproic acid on the pharmacokinetics and metabolic profile of topiramate at steady state in patients with epilepsy. Epilepsia 46, 1046–1054 (2005).

122.        Eyal, S., Yagen, B., Shimshoni, J. & Bialer, M. Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives. Biochem. Pharmacol. 69, 1501–1508 (2005).

123.        Okada, A., Kushima, K., Aoki, Y., Bialer, M. & Fujiwara, M. Identification of early-responsive genes correlated to valproic acid-induced neural tube defects in mice. Birth Defects Res. Part A - Clin. Mol. Teratol. 73, 229–238 (2005).

124.        Britzi, M. et al. Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine. Epilepsia 46, 378–384 (2005).

125.        Sobol, E. & Bialer, M. Critical analysis of the discrepancy between Vβ and Vss for drugs exhibiting different two-compartment disposition profiles. Biopharm. Drug Dispos. 26, 51–58 (2005).

126.        Bialer, M. Interactions of antiepileptic drugs. Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova 105, 59–60 (2005).

127.        Shank, R. P., Doose, D. R., Streeter, A. J. & Bialer, M. Plasma and whole blood pharmacokinetics of topiramate: The role of carbonic anhydrase. Epilepsy Res. 63, 103–112 (2005).

128.        Shaltiel, G. et al. Valproate decreases inositol biosynthesis. Biol. Psychiatry 56, 868–874 (2004).

129.        Bialer, M., Twyman, R. E. & White, H. S. Correlation analysis between anticonvulsant ED50 values of antiepileptic drugs in mice and rats and their therapeutic doses and plasma levels. Epilepsy Behav. 5, 866–872 (2004).

130.        Okada, A. et al. Polycomb homologs are involved in teratogenicity of valproic acid in mice. Birth Defects Res. Part A - Clin. Mol. Teratol. 70, 870–879 (2004).

131.        Bialer, M. et al. Pharmacokinetic interactions of topiramate. Clin. Pharmacokinet. 43, 763–780 (2004).

132.        Bialer, M. et al. Progress report on new antiepileptic drugs: A summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Res. 61, 1–48 (2004).

133.        Sobol, E., Bialer, M. & Yagen, B. Tetramethylcyclopropyl analogue of a leading antiepileptic drug, valproic acid. Synthesis and evaluation of anticonvulsant activity of its amide derivatives. J. Med. Chem. 47, 4316–4326 (2004).

134.        Eyal, S. et al. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 45, 737–744 (2004).

135.        Sobol, E. & Bialer, M. The relationships between half-life (t1/2) and mean residence time (MRT) in the two-compartment open body model. Biopharm. Drug Dispos. 25, 157–162 (2004).

136.        Gil-Nagel, A. et al. Evaluations and Awards at the Fifth European Congress of Epileptology, Madrid, 6-10 October 2002. Epilepsia 45, 396–398 (2004).

137.        Sobol, E. & Bialer, M. Mathematical comparison between volume of distribution (V) and volume of distribution at steady-state (VSS) utilizing model-indepent approach. Biopharm. Drug Dispos. 25, 99–101 (2004).

138.        Okada, A., Kurihara, H., Aoki, Y., Bialer, M. & Fujiwara, M. Amidic Modification of Valproic Acid Reduces Skeletal Teratogenicity in Mice. Birth Defects Res. Part B - Dev. Reprod. Toxicol. 71, 47–53 (2004).

139.        Isoherranen, N. et al. Metabolism of a new antiepileptic drug, N-methyl- tetramethylcyclopropanecarboxamide, and anticonvulsant activity of its metabolites. Epilepsy Res. 58, 1–12 (2004).

140.        Isoherranen, N. et al. Developmental Outcome of Levetiracetam, Its Major Metabolite in Humans, 2-Pyrrolidinone N-Butyric Acid, and Its Enantiomer (R)-α -ethyl-oxo-pyrrolidine Acetamide in a Mouse Model of Teratogenicity. Epilepsia 44, 1280–1288 (2003).

141.        Isoherranen, N. et al. Pharmacokinetic-pharmacodynamic relationships of (2S,3S)-valnoctamide and its stereoisomer (2R,3S)-valnoctamide in rodent models of epilepsy. Pharm. Res. 20, 1293–1301 (2003).

142.        Doose, D. R. et al. Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. Epilepsia 44, 917–922 (2003).

143.        Johannessen, S. I. et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther. Drug Monit. 25, 347–363 (2003).

144.        Britzi, M. et al. Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass spectrometry assay. Ther. Drug Monit. 25, 314–322 (2003).

145.        Isoherranen, N. et al. Anticonvulsant activity, teratogenicity and pharmacokinetics of novel valproyltaurinamide derivatives in mice. Br. J. Pharmacol. 139, 755–764 (2003).

146.        Isoherranen, N. et al. Gas chromatographic determination of novel valproyl taurinamide derivatives in mouse and dog plasma. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 788, 125–136 (2003).

147.        Isoherranen, N., Yagen, B. & Bialer, M. New CNS-active drugs which are second-generation valproic acid: Can they lead to the development of a magic bullet? Curr. Opin. Neurol. 16, 203–211 (2003).

148.        Isoherranen, N. et al. Characterization of the anticonvulsant profile and enantioselective pharmacokinetics of the chiral valproylamide propylisopropyl acetamide in rodents. Br. J. Pharmacol. 138, 602–613 (2003).

149.        Williams, J. et al. Interlaboratory variability in the quantification of new generation antiepileptic drugs based on external quality assessment data. Epilepsia 44, 40–45 (2003).

150.        Doose, D. R. et al. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia 44, 540–549 (2003).

151.        Sachdeo, R. C. et al. Erratum: Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients (Epilepsia (2002) 43 (691-696)). Epilepsia 43, 1273 (2002).

152.        Bialer, M. et al. Progress report on new antiepileptic drugs: A summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res. 51, 31–71 (2002).

153.        Sachdeo, R. C. et al. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia 43, 691–696 (2002).

154.        Isoherranen, N. et al. Anticonvulsant profile and teratogenicity of N-methyl-tetramethylcyclopropyl carboxamide: A new antiepileptic drug. Epilepsia 43, 115–126 (2002).

155.        Bialer, M. New antiepileptic drugs currently in clinical trials: Is there a strategy in their development? Ther. Drug Monit. 24, 85–90 (2002).

156.        Bialer, M., Walker, M. C. & Sander, J. W. Pros and cons for the development of new antiepileptic drugs. CNS Drugs 16, 285–289 (2002).

157.        Isoherranen, N. et al. Pharmacokinetics of levetiracetam and its enantiomer (R)-α-ethyl-2-oxo-pyrrolidine acetamide in dogs. Epilepsia 42, 825–830 (2001).

158.        Isherranen, N., Woodhead, J. H., Steve White, H. & Bialer, M. Anticonvulsant profile of valrocemide (TV1901): A new antiepileptic drug. Epilepsia 42, 831–836 (2001).

159.        Bialer, M. et al. Progress report on new antiepileptic drugs: A summary of the Fifth Eilat Conference (EILAT V). Epilepsy Res. 43, 11–58 (2001).

160.        Wasserman, M., Yagen, B., Blotnik, S., Papo, N. & Bialer, M. Stereoselective pharmacokinetic analysis and antiepileptic activity of n-2-hydroxypropyl valpromide, a central nervous system-active chiral valproylamide. Ther. Drug Monit. 23, 414–420 (2001).

161.        Spiegelstein, O. et al. Stereoselective pharmacokinetic analysis of valnoctamide, a CNS-active chiral amide analogue of valproic acid, in dogs, rats, and mice. Ther. Drug Monit. 22, 574–581 (2000).

162.        Britzi, M. et al. Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups. Ther. Drug Monit. 22, 510–516 (2000).

163.        Isoherranen, N. et al. Enantioselective analysis of levetiracetam and its enantiomer R-α- ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion trap mass spectrometric detection. J. Chromatogr. B Biomed. Sci. Appl. 745, 325–332 (2000).

164.        Spiegelstein, O. et al. Structure activity relationship of human microsomal epoxide hydrolase inhibition by amide and acid analogues of valproic acid. Pharm. Res. 17, 216–221 (2000).

165.        Volosov, A. et al. Simultaneous stereoselective high-performance liquid chromatographic determination of 10-hydroxycarbazepine and its metabolite carbamazepine- 10,11-trans-dihydrodiol in human urine. J. Chromatogr. B Biomed. Sci. Appl. 738, 419–425 (2000).

166.        Lindekens, H. et al. In vivo study of the effect of valpromide and valnoctamide in the pilocarpine rat model of focal epilepsy. Pharm. Res. 17, 1408–1413 (2000).

167.        Volosov, A., Yagen, B. & Bialer, M. Comparative stereoselective pharmacokinetic analysis of 10-hydroxycarbazepine after oral administration of its individual enantiomers and the racemic mixture to dogs. Epilepsia 41, 1107–1111 (2000).

168.        Spiegelstein, O. et al. Stereoselective pharmacokinetics and pharmacodynamics of propylisopropyl acetamide, a CNS-active chiral amide analog of valproic acid. Pharm. Res. 16, 1582–1588 (1999).

169.        Bialer, M. Pharmacokinetic considerations in the design of better and safer new antiepileptic drugs. J. Control. Release 62, 187–192 (1999).

170.        Spiegelstein, O., Bialer, M., Radatz, M., Nau, H. & Yagen, B. Enantioselective synthesis and teratogenicity of propylisopropyl acetamide, a CNS-active chiral amide analogue of valproic acid. Chirality 11, 645–650 (1999).

171.        Sussan, S., Dagan, A., Blotnik, S. & Bialer, M. The structural requirements for the design of antiepileptic-glycine derivatives. Epilepsy Res. 34, 207–220 (1999).

172.        Volosov, A., Sintov, A. & Bialer, M. Stereoselective pharmacokinetic analysis of the antiepileptic 10- hydroxycarbazepine in dogs. Ther. Drug Monit. 21, 219–223 (1999).

173.        Roeder, M., Spiegelstein, O., Schurig, V., Bialer, M. & Yagen, B. Absolute configuration of the four stereoisomers of valnoctamide (2- ethyl-3-methyl valeramide), a potentially new stereospecific antiepileptic and CNS drug. Tetrahedron Asymmetry 10, 841–853 (1999).

174.        Bialer, M. et al. Progress report on new antiepileptic drugs: A summary of The Fourth Eilat Conference (EILAT IV). Epilepsy Res. 34, 1–41 (1999).

175.        Volosov, A. & Bialer, M. Use of mean residence time to determine the magnitude of difference between rate constants and to calculate t(max) in the Bateman equation. Biopharm. Drug Dispos. 20, 3–9 (1999).

176.        Volosov, A. et al. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clin. Pharmacol. Ther. 66, 547–553 (1999).

177.        Sussan, S., Dagan, A. & Bialer, M. Pharmacokinetic analysis and anticonvulsant activity of glycine and glycinamide derivatives. Epilepsy Res. 33, 11–21 (1999).

178.        Spiegelstein, O., Yagen, B. & Bialer, M. Structure-pharmacokinetic-pharmacodynamic relationships of N-alkyl derivatives of the new antiepileptic drug valproyl glycinamide. Epilepsia 40, 545–552 (1999).

179.        Bialer, M. et al. Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine. Epilepsy Res. 32, 371–378 (1998).

180.        Bialer, M. et al. Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine. Epilepsia 39, 513–519 (1998).

181.        Blotnik, S., Bergman, F. & Bialer, M. Disposition of two tetramethylcyclopropane analogues of valpromide in the brain, liver, plasma and urine of rats. Eur. J. Pharm. Sci. 6, 93–98 (1998).

182.        Radatz, M., Ehlers, K., Yagen, B., Bialer, M. & Nau, H. Valnoctamide, valpromide and valnoctic acid are much less teratogenic in mice than valproic acid. Epilepsy Res. 30, 41–48 (1998).

183.        Bialer, M., Levy, R. H. & Perucca, E. Does carbamazepine have a narrow therapeutic plasma concentration range? Ther. Drug Monit. 20, 56–59 (1998).

184.        Hadad, S. & Bialer, M. Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide. Biopharm. Drug Dispos. 18, 557–566 (1997).

185.        Spiegelstein, O., Bialer, M. & Yagen, B. Isolation of N,N-dialkylated derivatives of valproylglycinamide from dog plasma by active charcoal adsorption and their quantification by high-performance liquid chromatography. J. Chromatogr. B Biomed. Appl. 698, 195–200 (1997).

186.        Blotnik, S., Bergman, F. & Bialer, M. The disposition of valproyl glycinamide and valproyl glycine in rats. Pharm. Res. 14, 873–878 (1997).

187.        Levi, M., Yagen, B. & Bialer, M. Pharmacokinetics and antiepileptic activity of valproyl hydroxamic acid derivatives. Pharm. Res. 14, 213–217 (1997).

188.        Bialer, M. et al. Erratum: Corrigendum to: ‘Conference report. Progress report on new antiepileptic drugs: A summary of the Third Eilat Conference’ [Epilepsy Res. 25 (1996) 299] (S0920121196000812). Epilepsy Res. 26, 465 (1997).

189.        Barel, S. et al. Stereoselective pharmacokinetic analysis of valnoctamide in healthy subjects and in patients with epilepsy. Clin. Pharmacol. Ther. 61, 442–449 (1997).

190.        Bialer, M. et al. Progress report on new antiepileptic drugs: A summary of the Third Eilat Conference. Epilepsy Res. 25, 299–319 (1996).

191.        Bialer, M. et al. Pharmacokinetic and pharmacodynamic analysis of (E)-2-ene valproyl derivatives of glycine and valproyl derivatives of nipecotic acid. Biopharm. Drug Dispos. 17, 565–575 (1996).

192.        Blotnik, S., Bergman, F. & Bialer, M. Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats. Drug Metab. Dispos. 24, 560–564 (1996).

193.        Bialer, M. et al. Pharmacokinetic Analysis and Antiepileptic Activity of Tetra-Methylcyclopropane Analogues of Valpromide. Pharm. Res. 13, 284–289 (1996).

194.        Perucca, E. & Bialer, M. The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine. Clin. Pharmacokinet. 31, 29–46 (1996).

195.        Hadad, S. & Bialer, M. Pharmacokinetic Analysis and Antiepileptic Activity of N-Valproyl Derivatives of GABA and Glycine. Pharm. Res. An Off. J. Am. Assoc. Pharm. Sci. 12, 905–910 (1995).

196.        Samara, E., Avnir, D., Ladkani, D. & Bialer, M. Pharmacokinetic analysis of diethylcarbonate prodrugs of ibuprofen and naproxen. Biopharm. Drug Dispos. 16, 201–210 (1995).

197.        Bialer, M. et al. Criteria to assess in vivo performance of sustained release products: Application to diltiazem formulations. J. Pharm. Sci. 84, 1160–1163 (1995).

198.        Stables, J. P. et al. Progress report on new antiepileptic drugs A summary of the Second Eilat Conference. Epilepsy Res. 22, 235–246 (1995).

199.        Abu Salach, O., Hadad, S., Haj-Yehia, A., Sussan, S. & Bialer, M. FC27 comparative pharmacokinetic and pharmacodynamic analysis of phthaloyl glycine derivatives with potential antiepileptic activity. Eur. J. Pharm. Sci. 2, 107 (1994).

200.        Bialer, M., Haj-Yehia, A., Badir, K. & Hadad, S. Can we develop improved derivatives of valproic acid? Pharm. World Sci. 16, 2–6 (1994).

201.        Bialer, M. et al. Pharmacokinetic analysis of valdice - a diethylcarbonate prodrug of valproic acid. Eur. J. Pharm. Sci. 2, 239–244 (1994).

202.        Barel, S., Yagen, B. & Bialer, M. Pharmacokinetic profile of conjugated verrucarol urinary metabolites in dogs. Biopharm. Drug Dispos. 15, 609–616 (1994).

203.        Perucca, E. et al. Inhibition of diazepam metabolism by fluvoxamine: A pharmacokinetic study in normal volunteers. Clin. Pharmacol. Ther. 56, 471–476 (1994).

204.        Bialer, M. et al. Pharmacokinetic analysis of two new sustained‐release products of diltiazem designed for twice‐and once‐daily treatment. Biopharm. Drug Dispos. 15, 45–52 (1994).

205.        Soback, S., Gips, M., Bialer, M. & Bor, A. Effect of lactation on single-dose pharmacokinetics of norfloxacin nicotinate in ewes. Antimicrob. Agents Chemother. 38, 2336–2339 (1994).

206.        Salach, O. A., Hadad, S., Haj-Yehia, A., Sussan, S. & Bialer, M. Comparative Pharmacokinetic and Pharmacodynamic Analysis of Phthaloyl Glycine Derivatives with Potential Antiepileptic Activity. Pharm. Res. An Off. J. Am. Assoc. Pharm. Sci. 11, 1429–1434 (1994).

207.        Pisani, F. et al. Interaction of Carbamazepine with Valnoctamide: Data ‘in vitro’ and in patients with epilepsy . Boll. - Lega Ital. contro l’Epilessia 159 (1993).

208.        Hadad, S., Vree, T. B., Van Der Kleijn, E. & Bialer, M. Pharmacokinetic analysis and anticonvulsant activity of two polyesteric prodrugs of valproic acid. Biopharm. Drug Dispos. 14, 51–59 (1993).

209.        Yagen, B. & Bialer, M. Metabolism and pharmacokinetics of t-2 toxin and related trichothecenes. Drug Metab. Rev. 25, 281–323 (1993).

210.        Bialer, M. Comparative Pharmacokinetics of the Newer Antiepileptic Drugs. Clin. Pharmacokinet. 24, 441–452 (1993).

211.        Gabizon, A. A., Barenholz, Y. & Bialer, M. Prolongation of the Circulation Time of Doxorubicin Encapsulated in Liposomes Containing a Polyethylene Glycol-Derivatized Phospholipid: Pharmacokinetic Studies in Rodents and Dogs. Pharm. Res. An Off. J. Am. Assoc. Pharm. Sci. 10, 703–708 (1993).

212.        Hadad, S., Vree, T. B., Kleijn, E. V. D. & Bialer, M. Pharmacokinetic analysis of ester prodrugs of valproic acid. J. Pharm. Sci. 81, 1047–1050 (1992).

213.        Haj-Yehia, A., Hadad, S. & Bialer, M. Pharmacokinetic Analysis of the Structural Requirements for Forming “Stable” Analogues of Valpromide. Pharm. Res. An Off. J. Am. Assoc. Pharm. Sci. 9, 1058–1063 (1992).

214.        Bialer, M. Pharmacokinetic Evaluation of Sustained Release Formulations of Antiepileptic Drugs: Clinical Implications. Clin. Pharmacokinet. 22, 11–21 (1992).

215.        Samara, E., Bialer, M. & Harvey, D. J. Metabolism of cannabidiol by the rat. Eur. J. Drug Metab. Pharmacokinet. 16, 305–313 (1991).

216.        Betlach, C. J. et al. The Effect of Raising Gastric pH with Ranitidine on the Absorption and Elimination of Theophylline from a Sustained-Release Theophylline Tablet. Pharm. Res. An Off. J. Am. Assoc. Pharm. Sci. 8, 1516–1519 (1991).

217.        Bialer, M. Clinical Pharmacology of Valpromide. Clin. Pharmacokinet. 20, 114–122 (1991).

218.        Badir, K., Haj-Yehia, A., Vree, T. B., van der Kleijn, E. & Bialer, M. Pharmacokinetics and Anticonvulsant Activity of Three Monoesteric Prodrugs of Valproic Acid. Pharm. Res. An Off. J. Am. Assoc. Pharm. Sci. 8, 750–753 (1991).

219.        McLean, A. M., Cefali, E. A., Roden, J. S., Gonzalez, M. A. & Bialer, M. Stability of diltiazem in different biological fluids. Biopharm. Drug Dispos. 12, 327–334 (1991).

220.        Samara, E., Bialer, M. & Harvey, D. J. Identification of urinary metabolites of cannabidiol in the dog. Drug Metab. Dispos. 18, 571–579 (1990).

221.        Billig, H., Ziv, E., Bar-on, H. & Bialer, M. The disposition of valpromide in rats and the isolated perfused rat liver. Drug Metab. Dispos. 18, 238–244 (1990).

222.        Bialer, M., Haj-Yehia, A., Barzaghi, N., Pisani, F. & Perucca, E. Pharmacokinetics of a valpromide isomer, valnoctamide, in healthy subjects. Eur. J. Clin. Pharmacol. 38, 289–291 (1990).

223.        Samara, E., Bialer, M. & Harvey, D. J. Pharmacokinetics of urinary metabolites of cannabidiol in the dog. Biopharm. Drug Dispos. 11, 785–795 (1990).

224.        Barel, S., Yagen, B. & Bialer, M. Pharmacokinetics of the trichothecene mycotoxin verrucarol in dogs. J. Pharm. Sci. 79, 548–551 (1990).

225.        Samara, E., Bialer, M., Bar-On, H. & Harvey, D. J. Identification of metabolites of the 1’1’dimethylheptyl analogue of cannabidiol in rat and dog in viv. Xenobiotica 20, 447–455 (1990).

226.        McLean, A. M., Ruggirello, D. A., Banfield, C., Gonzalez, M. A. & Bialer, M. Application of a variance‐stabilizing transformation approach to linear regression of calibration lines. J. Pharm. Sci. 79, 1005–1008 (1990).

227.        Samara, E., Bialer, M. & Harvey, D. J. Identification of glucose conjugates as major urinary metabolites of cannabidiol in the dog. Xenobiotica 20, 177–183 (1990).

228.        Haj‐Yehia, A. & Bialer, M. Structure–pharmacokinetic relationships in a series of short fatty acid amides that possess anticonvulsant activity. J. Pharm. Sci. 79, 719–724 (1990).

229.        Haj-Yehia, A. & Bialer, M. Structure–Pharmacokinetic Relationships in a Series of Valpromide Derivatives with Antiepileptic Activity. Pharm. Res. An Off. J. Am. Assoc. Pharm. Sci. 6, 683–689 (1989).

230.        David, J. B. & Bialer, M. Pharmacokinetic interaction between diltiazem and amiodarone in the dog. Biopharm. Drug Dispos. 10, 423–429 (1989).

231.        Mason, E. J. & Bialer, M. The logical structure and validity of experimental designs in pharmacokinetics and clinical pharmacology. Biopharm. Drug Dispos. 10, 331–351 (1989).

232.        Samara, E. & Bialer, M. Pharmacokinetics of the dimethylheptyl homolog of cannabidiol in dogs. Drug Metab. Dispos. 16, 875–879 (1988).

233.        Maislos, M., Bialer, M., Mead, P. M. & Robbins, D. C. Pharmacokinetic model of circulating covalent aggregates of insulin. Diabetes 37, 1059–1063 (1988).

234.        Haj‐Yehia, A. & Bialer, M. Pharmacokinetics of a valpromide isomer, valnoctamide, in dogs. J. Pharm. Sci. 77, 831–834 (1988).

235.        Sintov, A., Bialer, M. & Yagen, B. Pharmacokinetics and protein binding of trichothecene mycotoxins, T-2 toxin and HT-2 toxin, in dogs. Toxicon 26, 153–160 (1988).

236.        Samara, E., Bialer, M. & Mechoulam, R. Pharmacokinetics of cannabidiol in dogs. Drug Metab. Dispos. 16, 469–472 (1988).

237.        Bialer, M., Wu, W. H., Faulkner, R. D., Michael Silber, B. & Yacobi, A. In vitro protein binding interaction studies involving cefixime. Biopharm. Drug Dispos. 9, 315–320 (1988).

238.        Bialer, M., Wu, W. H., Look, Z. M., Silber, B. M. & Yacobi, A. Pharmacokinetics of cefixime after oral and intravenous doses in dogs: Bioavailability assessment for a drug showing nonlinear serum protein binding. Res. Commun. Chem. Pathol. Pharmacol. 56, 21–32 (1987).

239.        Sintov, A., Bialer, M. & Yagen, B. Pharmacokinetics of t-2 tetraol, a urinary metabolite of the trichothecene mycotoxin, t-2 toxin, in dog. Xenobiotica 17, 941–950 (1987).

240.        Samara, E. & Bialer, M. Rapid high-performance liquid chromatographic assay with pharmacokinetic applications for monitoring cannabidiol in plasma. J. Chromatogr. B Biomed. Sci. Appl. 416, 370–374 (1987).

241.        Hussein, Z., Bialer, M., Friedman, M. & Raz, I. Pharmacokinetic analysis of sustained‐release dosage forms of theophylline in humans: Comparison of single and multiple dose studies. Biopharm. Drug Dispos. 8, 427–435 (1987).

242.        Hussein, Z., Bialer, M., Friedman, M. & Raz, I. Comparative pharmacokinetic evaluation of sustained-release theophylline formulations in dogs and humans. Int. J. Pharm. 37, 97–102 (1987).

243.        Bialer, M. et al. Dose-Dependent Pharmacokinetics of a New Oral Cephalosporin, Cefixime, in the Dog. Pharm. Res. An Off. J. Am. Assoc. Pharm. Sci. 4, 33–37 (1987).

244.        Tonelli, A. P., Bialer, M., Look, Z. M., Carson, S. & Yacobi, A. Saturable Processes Affecting Renal Clearance of Cefixime in Dogs. Pharm. Res. An Off. J. Am. Assoc. Pharm. Sci. 3, 150–155 (1986).

245.        Rubinstein, A., Bialer, M., Friedman, M., Raz, I. & Abramsky, O. A combined approach to control valproic acid release via novel delivery system of valpromide: A kinetic and pharmacokinetic study. J. Control. Release 4, 33–38 (1986).

246.        Bialer, M., Look, Z. M., Silber, B. M. & Yacobi, A. The relationship between drug input and mean residence time in the body. Biopharm. Drug Dispos. 7, 577–583 (1986).

247.        Pei, Y. ‐Y., Bialer, M. & Levy, R. H. Effects of phenobarbital steady state levels on antipyrine clearance and distribution in the rat. Biopharm. Drug Dispos. 7, 11–19 (1986).

248.        Sintov, A., Bialer, M. & Yagen, B. Pharmacokinetics of T-2 toxin and its metabolite HT-2 toxin, after intravenous adminstration in dogs. Drug Metab. Dispos. 14, 250–254 (1986).

249.        Bialer, M., Tonelli, A. P., Kantrowitz, J. D. & Yacobi, A. Serum protein binding of a new oral cephalosporin, CL 284,635, in various species. Drug Metab. Dispos. 14, 132–136 (1986).

250.        Bialer, M., Friedman, M. & Dubrovsky, J. Relation between absorption half‐life values of four novel sustained‐release dosage forms of valproic acid in dogs and human. Biopharm. Drug Dispos. 7, 495–500 (1986).

251.        Yagen, B., Sintov, A. & Bialer, M. New, sensitive thin-layer chromatographic-high-performance liquid chromatographic method for detection of trichothecene mycotoxins. J. Chromatogr. A 356, 195–201 (1986).

252.        Bialer, M., Salame, K. & Raz, I. Effect of sustained-release on the pharmacokinetics of theophylline in healthy subjects. Int. J. Clin. Pharmacol. Ther. Toxicol. 23, 662–667 (1985).

253.        Tonelli, A. P., Bialer, M. & Yacobi, A. Relationship between protein binding and renal clearance of a new oral cephalosporin in the dog. J. Pharm. Sci. 74, 1242–1244 (1985).

254.        Yagen, B., Bialer, M. & Sintov, A. Gas chromatographic assay with pharmacokinetic applications for monitoring T-2 and HT-2 toxins in plasma. J. Chromatogr. B Biomed. Sci. Appl. 343, 67–75 (1985).

255.        Bialer, M., Friedman, M., Dubrovsky, J., Raz, I. & Abramsky, O. Pharmacokinetic evaluation of novel sustained‐release dosage forms of valproic acid in humans. Biopharm. Drug Dispos. 6, 401–411 (1985).

256.        Bialer, M. et al. Pharmacokinetics of valproic acid in volunteers after a single dose study. Biopharm. Drug Dispos. 6, 33–42 (1985).

257.        Bialer, M. & Hoch, B. Rapid gas chromatographic assay for monitoring valnoctamide in plasma. J. Chromatogr. B Biomed. Sci. Appl. 337, 408–411 (1985).

258.        Bialer, M., Rubinstein, A., Dubrovsky, J., Raz, I. & Abramsky, O. A comparative pharmacokinetic study of valpromide and valproic acid after intravenous administration in humans. Int. J. Pharm. 23, 25–33 (1985).

259.        Bialer, M., Hussein, Z., Dubrovsky, J., Raz, I. & Abramsky, O. Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans. Isr. J. Med. Sci. 20, 46–49 (1984).

260.        Bialer, M., Rubinstein, A., Raz, I. & Abramsky, O. Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers. Eur. J. Clin. Pharmacol. 27, 501–503 (1984).

261.        Raz, I., Bialer, M., Salame, K. & Bar-On, H. Comparative pharmacokinetic analysis of a novel sustained-release dosage form of theophylline in humans. Eur. J. Clin. Pharmacol. 26, 401–403 (1984).

262.        Bialer, M., Friedman, M. & Dubrovsky, J. Comparative pharmacokinetic analysis of a novel sustained release dosage form of valproic acid in dogs. Biopharm. Drug Dispos. 5, 1–10 (1984).

263.        Bialer, M., Friedman, M. & Dubrovsky, J. Effect of sustained release on the pharmacokinetics of valproic acid in the dog. Int. J. Pharm. 20, 53–63 (1984).

264.        Bialer, M., Friedman, M. & Rubinstein, A. Rapid gas chromatographic assay for monitoring valproic acid and valpromide in plasma. J. Pharm. Sci. 73, 991–993 (1984).

265.        Bialer, M. & Rubinstein, A. Pharmacokinetics of valpromide in dogs after various modes of administration. Biopharm. Drug Dispos. 5, 177–183 (1984).

266.        Bialer, M., Sloneker, S. D. & Kostenbauder, H. B. Isolation of a cigarette smoke fraction responsible for the inhibition of benzo[a]pyrene metabolism in the isolated perfused rabbit lung. Chem. Biol. Interact. 51, 309–320 (1984).

267.        Johno, I., Bialer, M., Nickelson, S. A. & Levy, R. H. Disposition of Progabide and Valproic Acid Following Intraperitoneal Administration in Rhesus Monkey. Epilepsia 25, 578–585 (1984).

268.        Bialer, M. Estimation of pharmacokinetic parameters in extravascular multiple dose administration in the one-compartment open body model with equal absorption and elimination first-order rate constants. Int. J. Pharm. 13, 345–348 (1983).

269.        Bialer, M., Hussein, Z., Herishanu, Y. & Melnik, Y. An alternative method for calculating absorption and elimination rate constants in first-order processes: application to valproic acid. Int. J. Pharm. 16, 285–294 (1983).

270.        Bialer, M. & Rubinstein, A. A comparative study on the pharmacokinetics of valpramide after intravenous administration in dogs. J. Pharm. Pharmacol. 35, 607–609 (1983).

271.        Garrett, E. R., Green  Jr., J. R. & Bialer, M. Bretylium pharmacokinetics and bioavailabilities in man with various doses and modes of administration. Biopharm. Drug Dispos. 3, 129–164 (1982).

272.        Bialer, M. An unusual cleavage of ring D in Δ14-17-keto steroid after a reaction with alkaline hydrogen peroxide. Tetrahedron Lett. 22, 2683–2684 (1981).

273.        Bialer, M., El‐On, J., Yagen, B. & Mechoulam, R. Antiparasitic structure‐activity relationships of congocidine derivatives. J. Pharm. Sci. 70, 822–824 (1981).

274.        Bourne, D. W. A. et al. Disposition of sulfadimethoxine in cattle: Inclusion of protein binding factors in a pharmacokinetic model. J. Pharm. Sci. 70, 1068–1072 (1981).

275.        Bialer, M. An alternative method for calculating simple pharmacokinetic parameters for zero‐order absorption and first‐order elimination processes. Biopharm. Drug Dispos. 2, 323–327 (1981).

276.        Bialer, M., Yagen, B., Mechoulam, R. & Becker, Y. Structure-Activity Relationships of Pyrrole Amidine Antiviral Antibiotics. 2. Preparation of Mono-and Tripyrrole Derivatives of Congocidine. J. Med. Chem. 23, 1144–1148 (1980).

277.        Bialer, M. A simple method for determining whether absorption and elimination rate constants are equal in the one-compartment open model with first-order processes. J. Pharmacokinet. Biopharm. 8, 111–113 (1980).

278.        Bialer, M., Yagen, B., Mechoulam, R. & Becker, Y. Structure–activity relationships of pyrrole amidine antiviral antibiotics III: Preparation of distamycin and congocidine derivatives based on 2,5‐disubstituted pyrroles. J. Pharm. Sci. 69, 1334–1338 (1980).

279.        Bialer, M., Yagen, B. & Mechoulam, R. Structure elucidation of a condensation product of 4‐aminopyrrole derivatives and dicyclohexylcarbodiimide. J. Heterocycl. Chem. 17, 1797–1798 (1980).

280.        Bialer, M., Yagen, B., Mechoulam, R. & Becker, Y. Structure-Activity Relationships of Pyrrole Amidine Antiviral Antibiotics. 1. Modifications of the Alkylamidine Side Chain. J. Med. Chem. 22, 1296–1301 (1979).

281.        Bialer, M., Yagen, B. & Mechoulam, R. A total synthesis of distamycin a, an antiviral antibiotic. Tetrahedron 34, 2389–2391 (1978).